Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells
Glioblastoma multiforme (GBM) is the most prevalent and aggressive brain tumor. The current standard therapy, which includes radiation and chemotherapy, is frequently ineffective partially because of drug resistance and poor penetration of the blood-brain barrier. Reducing resistance and increasing sensitivity to chemotherapy may improve outcomes. Glioma stem cells (GSCs) are a source of relapse and chemoresistance in GBM; sensitization of GSCs to temozoliomide (TMZ), the primary chemotherapeutic agent used to treat GBM, is therefore integral for therapeutic efficacy.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Hyangsoon Noh, Qingnan Zhao, Jun Yan, Ling-Yuan Kong, Konrad Gabrusiewicz, Sungguan Hong, Xueqing Xia, Amy B. Heimberger, Shulin Li Tags: Original Articles Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Glioma | Neurology | Stem Cell Therapy | Stem Cells | Temodar